MARKET

ATRS

ATRS

Antares Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.870
+0.070
+1.84%
After Hours: 3.900 +0.03 +0.78% 18:02 05/11 EDT
OPEN
3.750
PREV CLOSE
3.800
HIGH
3.940
LOW
3.690
VOLUME
733.90K
TURNOVER
--
52 WEEK HIGH
5.07
52 WEEK LOW
2.390
MARKET CAP
653.25M
P/E (TTM)
11.80
1D
5D
1M
3M
1Y
5Y
Transdermal Patch Drug Delivery System Market 2021 Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive, Regional, And Global Forecast To 2026
May 11, 2021 (The Expresswire) -- Global "Transdermal Patch Drug Delivery System Market"(2021-2026) provides an all-inclusive assessment of the market and...
The Express Wire · 14h ago
Global Needle Free Injection Market Current Analysis and Estimated Forecast to 2027 | Medical International Technology, Inc., Antares Pharma, Inc., PharmaJet, PenJet Corporation
May 11, 2021 (AmericaNewsHour) -- The report titled "Global Needle Free Injection Market: Global Demand Analysis & Opportunity Outlook 2027" delivers...
AmericaNewsHour · 16h ago
Antares Pharma Posts Clinical Trial Titled 'Phase 1 Study of ATRS-2002 in Healthy Male Adults' To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT04879589
Benzinga · 1d ago
HC Wainwright & Co. Maintains Buy on Antares Pharma, Raises Price Target to $5
HC Wainwright & Co. analyst Oren Livnat maintains Antares Pharma (NASDAQ:ATRS) with a Buy and raises the price target from $4.5 to $5.
Benzinga · 1d ago
DJ Antares Pharma Price Target Raised to $5.00/Share From $4.50 by HC Wainwright & Co.
Dow Jones · 1d ago
DJ Antares Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Transmucosal Drug Delivery Devices Market Analysis, Trends, Share, Key Players, Size, Forecast to 2026
May 07, 2021 (Market Insight Reports) -- Selbyville, Delaware, Transmucosal Drug Delivery Devices Market research report examines key market opportunities...
Market Insight Reports · 4d ago
Global Liquid-based Needle-Free Injector Market 2021 Worldwide Analysis of Growth Segments, Top Countries Data, Recent Trends, Opportunities by Leading Players, CAGR Status and SWOT Analysis till 2027
May 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Liquid-based Needle-Free Injector...
The Express Wire · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRS. Analyze the recent business situations of Antares Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRS stock price target is 6.50 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 235
Institutional Holdings: 82.16M
% Owned: 48.67%
Shares Outstanding: 168.80M
TypeInstitutionsShares
Increased
51
3.24M
New
24
10.35M
Decreased
52
3.09M
Sold Out
12
4.38M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.71%
Healthcare Equipment & Supplies
-0.50%
Key Executives
Chairman/Independent Director
Leonard Jacob
President/Chief Executive Officer/Director
Robert Apple
Chief Financial Officer/Executive Vice President
Fred Powell
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Peter Graham
Executive Vice President
Peter Richardson
Independent Director
Thomas Garrity
Independent Director
Peter Greenleaf
Independent Director
Anton Gueth
Independent Director
Robert Roche
Independent Director
Karen Smith
No Data
About ATRS
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Webull offers kinds of Antares Pharma Inc stock information, including NASDAQ:ATRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRS stock methods without spending real money on the virtual paper trading platform.